The Developmental Research Program (DRP) is designed to provide funding to initiate promising translational studies with a focus on brain tumors. High priority will be given to projects that will generate clinically-relevant hypotheses aimed at reducing the morbidity or mortality of brain tumors or improving the quality of life of patients with brain tumors. At least annually, proposals for innovative translational brain tumor research will be solicited throughout all institutions in the Texas Medical Center. It is anticipated that some applicants will be without extensive experience in preparing successful research proposals; therefore, the DRP Co-Directors will help investigators formulate specific aims and research plans that are translational in nature, with realistic and appropriate budgets. Thus, in addition to developing promising research projects for the SPORE program, the DRP will also be a major educational activity that will further enhance the initiation and development of innovative translational research concepts in brain cancer. The SPORE Executive Committee will screen proposals for appropriate SPORE qualifications using objective criteria. The selected proposals will then undergo scientific review and prioritization by members of the SPORE External Advisory Board;final selection of the research projects to be funded will be made on the basis of these reviews. A two-year funding period will be allowed, with allocation of funds for the second year to be made after satisfactory review of a written progress report from the awardee. Additional funding may be granted, if it is felt that an additional year of work will lead to independent peer-reviewed funding and/or lead to significant enhancement in diagnosis or treatment of brain tumors;requests for this additional funding will be very carefully reviewed by the SPORE Executive Committee and External Advisory Board. As part of our continuing efforts to expand brain tumor research at The University of Texas M. D. Anderson Cancer Center and in anticipation of this SPORE application, developmental research projects were solicited;the four projects considered to be of highest potential and consistent with the translational focus of the SPORE are included here and represent those that will be considered for funding to begin in Year 1 of the SPORE program. These projects illustrate the breadth and depth of interest in brain tumor translational research at our institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127001-05
Application #
8380399
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$144,228
Indirect Cost
$45,559
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Figueroa, Javier; Phillips, Lynette M; Shahar, Tal et al. (2017) Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Res 77:5808-5819
Narang, Shivali; Kim, Donnie; Aithala, Sathvik et al. (2017) Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget 8:101244-101254
Carstens, Julienne L; Correa de Sampaio, Pedro; Yang, Dalu et al. (2017) Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8:15095
Hu, Jingzhe; Salzillo, Travis C; Sailasuta, Napapon et al. (2017) Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization. Top Magn Reson Imaging 26:27-32
Lehrer, Michael; Bhadra, Anindya; Ravikumar, Visweswaran et al. (2017) Multiple-response regression analysis links magnetic resonance imaging features to de-regulated protein expression and pathway activity in lower grade glioma. Oncoscience 4:57-66
Koul, Dimpy; Wang, Shuzhen; Wu, Shaofang et al. (2017) Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget 8:21741-21753
Qian, Xu; Li, Xinjian; Cai, Qingsong et al. (2017) Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy. Mol Cell 65:917-931.e6
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2017) Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23:2891-2904
Gressot, Loyola V; Doucette, Tiffany; Yang, Yuhui et al. (2017) Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma. Oncotarget 8:12695-12704
Jiang, Hong; Rivera-Molina, Yisel; Gomez-Manzano, Candelaria et al. (2017) Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77:3894-3907

Showing the most recent 10 out of 208 publications